The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.
 
Clarissa Mathias
No Relationships to Disclose
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health AMEA; Janssen; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Carolin Gross-Ophoff-Mueller
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Janssen; Novocure
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Pierre Fabre
 
Shun Lu
Leadership - Innovent BIOLOGICS, INC; Shanghai Fosun; Simcere Zaiming
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - MSD; Roche
 
Alona Zer
Honoraria - AstraZeneca; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD; Pfizer; Roche
Consulting or Advisory Role - BeiGene; Boehringer Ingelheim; Gilead Sciences; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - Beyond Air
 
Moritz Drachsler
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Maozhen Gong
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
James Hurlock
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jakub Tyszecki
Employment - AstraZeneca
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics